Grifols, S.A. (NASDAQ:GRFS) Shares Sold by First Trust Direct Indexing L.P.

First Trust Direct Indexing L.P. trimmed its position in Grifols, S.A. (NASDAQ:GRFS) by 12.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,872 shares of the biotechnology company’s stock after selling 6,585 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in Grifols were worth $553,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Raymond James & Associates acquired a new position in Grifols during the third quarter valued at approximately $254,000. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Grifols by 6.5% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 178,413 shares of the biotechnology company’s stock worth $1,631,000 after purchasing an additional 10,954 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Grifols by 106.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,132 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,618 shares in the last quarter. Syon Capital LLC acquired a new stake in shares of Grifols in the third quarter valued at about $250,000. Finally, NBC Securities Inc. purchased a new stake in shares of Grifols during the 3rd quarter valued at about $259,000.

Grifols Stock Up 2.8 %

Shares of NASDAQ GRFS opened at $6.57 on Monday. The company has a quick ratio of 1.29, a current ratio of 2.79 and a debt-to-equity ratio of 1.26. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15. The stock’s 50-day simple moving average is $6.70 and its 200-day simple moving average is $8.24.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft downgraded shares of Grifols from a “hold” rating to a “sell” rating in a research report on Tuesday, March 12th.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.